MedTrace Logo

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

NCT05329103 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2026-05-15

No results posted yet for this study

Summary

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

PEEL-224

Lyophilized powder reconstituted with D5W

DRUG

FOLF+B

infusional 5-FU, LV, and bevacizumab

Sponsors & Collaborators

  • Peel Therapeutics Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-11
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329103 on ClinicalTrials.gov